vs

Side-by-side financial comparison of ASTRONICS CORP (ATRO) and Orthofix Medical Inc. (OFIX). Click either name above to swap in a different company.

ASTRONICS CORP is the larger business by last-quarter revenue ($240.1M vs $219.9M, roughly 1.1× Orthofix Medical Inc.). On growth, ASTRONICS CORP posted the faster year-over-year revenue change (15.1% vs 2.0%). Orthofix Medical Inc. produced more free cash flow last quarter ($16.8M vs $15.8M). Over the past eight quarters, ASTRONICS CORP's revenue compounded faster (13.9% CAGR vs 8.0%).

Astronics Corporation is an American aerospace electronics corporation founded in 1968, headquartered in East Aurora, New York. It is traded on NASDAQ as Nasdaq: ATRO. It is known for lighting and electronics integrations on military, commercial, and business aircraft and semiconductor test systems.

Orthofix Medical Inc. is a global medical device firm specializing in orthopedic care. It develops, manufactures and sells spinal implants, trauma care products, bone growth stimulation therapies and regenerative medicine offerings, serving orthopedic surgeons and healthcare providers across North America, Europe and Asia Pacific.

ATRO vs OFIX — Head-to-Head

Bigger by revenue
ATRO
ATRO
1.1× larger
ATRO
$240.1M
$219.9M
OFIX
Growing faster (revenue YoY)
ATRO
ATRO
+13.1% gap
ATRO
15.1%
2.0%
OFIX
More free cash flow
OFIX
OFIX
$1.0M more FCF
OFIX
$16.8M
$15.8M
ATRO
Faster 2-yr revenue CAGR
ATRO
ATRO
Annualised
ATRO
13.9%
8.0%
OFIX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ATRO
ATRO
OFIX
OFIX
Revenue
$240.1M
$219.9M
Net Profit
$-2.2M
Gross Margin
33.3%
71.1%
Operating Margin
14.8%
0.2%
Net Margin
-1.0%
Revenue YoY
15.1%
2.0%
Net Profit YoY
92.4%
EPS (diluted)
$0.82
$-0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ATRO
ATRO
OFIX
OFIX
Q4 25
$240.1M
$219.9M
Q3 25
$211.4M
$205.6M
Q2 25
$204.7M
$203.1M
Q1 25
$205.9M
$193.6M
Q4 24
$208.5M
$215.7M
Q3 24
$203.7M
$196.6M
Q2 24
$198.1M
$198.6M
Q1 24
$185.1M
$188.6M
Net Profit
ATRO
ATRO
OFIX
OFIX
Q4 25
$-2.2M
Q3 25
$-11.1M
$-22.8M
Q2 25
$1.3M
$-14.1M
Q1 25
$9.5M
$-53.1M
Q4 24
$-29.1M
Q3 24
$-11.7M
$-27.4M
Q2 24
$1.5M
$-33.4M
Q1 24
$-3.2M
$-36.0M
Gross Margin
ATRO
ATRO
OFIX
OFIX
Q4 25
33.3%
71.1%
Q3 25
30.5%
72.2%
Q2 25
25.8%
68.7%
Q1 25
29.5%
62.8%
Q4 24
29.8%
69.0%
Q3 24
27.1%
68.7%
Q2 24
28.0%
67.8%
Q1 24
25.7%
67.5%
Operating Margin
ATRO
ATRO
OFIX
OFIX
Q4 25
14.8%
0.2%
Q3 25
10.9%
-8.3%
Q2 25
2.3%
-7.9%
Q1 25
6.4%
-25.2%
Q4 24
4.3%
-5.3%
Q3 24
4.1%
-9.6%
Q2 24
3.8%
-12.5%
Q1 24
0.9%
-15.6%
Net Margin
ATRO
ATRO
OFIX
OFIX
Q4 25
-1.0%
Q3 25
-5.2%
-11.1%
Q2 25
0.6%
-6.9%
Q1 25
4.6%
-27.4%
Q4 24
-13.5%
Q3 24
-5.8%
-13.9%
Q2 24
0.8%
-16.8%
Q1 24
-1.7%
-19.1%
EPS (diluted)
ATRO
ATRO
OFIX
OFIX
Q4 25
$0.82
$-0.05
Q3 25
$-0.31
$-0.57
Q2 25
$0.04
$-0.36
Q1 25
$0.26
$-1.35
Q4 24
$-0.07
$-0.76
Q3 24
$-0.34
$-0.71
Q2 24
$0.04
$-0.88
Q1 24
$-0.09
$-0.95

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ATRO
ATRO
OFIX
OFIX
Cash + ST InvestmentsLiquidity on hand
$18.2M
$82.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$140.1M
$450.0M
Total Assets
$706.7M
$850.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ATRO
ATRO
OFIX
OFIX
Q4 25
$18.2M
$82.0M
Q3 25
$13.5M
$62.9M
Q2 25
$13.5M
$65.6M
Q1 25
$24.8M
$58.0M
Q4 24
$9.3M
$83.2M
Q3 24
$5.2M
$30.1M
Q2 24
$2.9M
$26.4M
Q1 24
$5.3M
$27.0M
Total Debt
ATRO
ATRO
OFIX
OFIX
Q4 25
Q3 25
$157.2M
Q2 25
$157.0M
Q1 25
$156.9M
Q4 24
$157.0M
Q3 24
$118.5M
Q2 24
$118.0M
Q1 24
$118.2M
Stockholders' Equity
ATRO
ATRO
OFIX
OFIX
Q4 25
$140.1M
$450.0M
Q3 25
$108.9M
$442.5M
Q2 25
$271.6M
$458.3M
Q1 25
$266.8M
$458.3M
Q4 24
$256.1M
$503.1M
Q3 24
$249.2M
$525.9M
Q2 24
$257.9M
$546.0M
Q1 24
$251.7M
$570.3M
Total Assets
ATRO
ATRO
OFIX
OFIX
Q4 25
$706.7M
$850.6M
Q3 25
$682.2M
$832.6M
Q2 25
$646.7M
$837.2M
Q1 25
$662.2M
$823.1M
Q4 24
$648.8M
$893.3M
Q3 24
$651.6M
$867.9M
Q2 24
$644.9M
$882.0M
Q1 24
$630.0M
$906.0M
Debt / Equity
ATRO
ATRO
OFIX
OFIX
Q4 25
Q3 25
0.36×
Q2 25
0.34×
Q1 25
0.34×
Q4 24
0.31×
Q3 24
0.23×
Q2 24
0.22×
Q1 24
0.21×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ATRO
ATRO
OFIX
OFIX
Operating Cash FlowLast quarter
$27.6M
$27.7M
Free Cash FlowOCF − Capex
$15.8M
$16.8M
FCF MarginFCF / Revenue
6.6%
7.6%
Capex IntensityCapex / Revenue
4.9%
4.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$43.1M
$-1.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ATRO
ATRO
OFIX
OFIX
Q4 25
$27.6M
$27.7M
Q3 25
$34.2M
$12.4M
Q2 25
$-7.6M
$11.6M
Q1 25
$20.6M
$-18.4M
Q4 24
$26.4M
$23.7M
Q3 24
$8.4M
$11.7M
Q2 24
$-6.3M
$9.0M
Q1 24
$2.0M
$-18.6M
Free Cash Flow
ATRO
ATRO
OFIX
OFIX
Q4 25
$15.8M
$16.8M
Q3 25
$21.0M
$2.5M
Q2 25
$-12.2M
$4.5M
Q1 25
$18.5M
$-25.1M
Q4 24
$23.2M
$15.2M
Q3 24
$6.5M
$6.3M
Q2 24
$-8.1M
$-360.0K
Q1 24
$439.0K
$-29.1M
FCF Margin
ATRO
ATRO
OFIX
OFIX
Q4 25
6.6%
7.6%
Q3 25
9.9%
1.2%
Q2 25
-6.0%
2.2%
Q1 25
9.0%
-13.0%
Q4 24
11.1%
7.0%
Q3 24
3.2%
3.2%
Q2 24
-4.1%
-0.2%
Q1 24
0.2%
-15.4%
Capex Intensity
ATRO
ATRO
OFIX
OFIX
Q4 25
4.9%
4.9%
Q3 25
6.2%
4.8%
Q2 25
2.2%
3.5%
Q1 25
1.0%
3.5%
Q4 24
1.5%
4.0%
Q3 24
0.9%
2.7%
Q2 24
0.9%
4.7%
Q1 24
0.9%
5.6%
Cash Conversion
ATRO
ATRO
OFIX
OFIX
Q4 25
Q3 25
Q2 25
-5.81×
Q1 25
2.17×
Q4 24
Q3 24
Q2 24
-4.08×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ATRO
ATRO

Product Line Electrical Power And Motion$113.8M47%
Product Line Avionics$32.0M13%
Military Aircraft$28.0M12%
General Aviation$22.3M9%
Government And Defense$20.5M9%
Product Line Systems Certification$13.2M6%
Product Line Structures$3.7M2%
Product Line Other$2.3M1%

OFIX
OFIX

Spinal Implants Biologics And Enabling Technologies$113.6M52%
Bone Growth Therapies$68.3M31%
Other$22.7M10%
IT$5.9M3%
GB$3.5M2%
FR$3.5M2%
DE$2.3M1%

Related Comparisons